Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Coles, Alasdair J, Jones, Joanne L, Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D, Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978465/
https://www.ncbi.nlm.nih.gov/pubmed/34882037
http://dx.doi.org/10.1177/13524585211061335
Descripción
Sumario:Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunity developed non-MS autoimmunity. Thyroid autoimmunity after alemtuzumab courses 1 or 2 did not increase subsequent non-thyroid autoimmune adverse events. Therefore, autoimmune disease before or after alemtuzumab treatment does not predict autoimmunity after further courses, so should not preclude adequate alemtuzumab dosing to control MS. Finally, post-marketing safety data contribute toward a full record of the alemtuzumab benefit/risk profile for the MS field.

Ejemplares similares